Pscilly

Reviews of TACT-908 (2ZEDMA) – Benzofuran-based 5-HT1B/5-HT2A agonist

No reviews yet. Share the first one.

TACT-908 (2ZEDMA) – Benzofuran-based 5-HT1B/5-HT2A agonist by Tactogen, Inc.

TACT-908 is an investigational candidate being developed for cluster headache. It is in preclinical development. Investigational; not for sale.

Guides about TACT-908 (2ZEDMA) – Benzofuran-based 5-HT1B/5-HT2A agonist

Related news

More from Tactogen, Inc.